Publications by authors named "M Andreansky"
Article Synopsis
- G-CSF after hematopoietic stem cell transplantation (HSCT) improves neutrophil recovery in neutropenic patients, but its safety in sickle cell disease (SCD) patients was previously unknown.
- Clinical outcomes were studied in 62 SCD patients receiving G-CSF post-HSCT, showing effective neutrophil and platelet engraftment without any SCD-related complications.
- Common post-treatment issues included anorexia, hypertension, and electrolyte imbalances, but overall, G-CSF was determined to be safe for SCD patients following HSCT.
Rehabilitation and physical activity for COVID-19 patients in the post infection period.
Bratisl Lek Listy
April 2021
The first cases of COVID-19 were initially recorded in December 2019 in Wuhan, the capital of China's Hubei Province. The situation quickly escalated and turned into a global pandemic. COVID-19 is a highly infectious respiratory disease that leads to decreased respiratory, physical, and psychological function of affected patients (2).
View Article and Find Full Text PDFHematopoietic stem cell transplantation (HSCT) is a therapeutic option for many nonmalignant disorders (NMD) and is curative or prevents disease progression. Reduced-intensity conditioning (RIC) in HSCT for NMD may reduce regimen-related acute toxicities and late complications. Myeloablation is often replaced by immune suppression in RIC regimens to support donor engraftment.
View Article and Find Full Text PDFAllogeneic hematopoietic stem cell transplantation (HSCT) can cure transfusion-dependent thalassemia (TDT). In a multicenter trial we investigated the efficacy of reduced-intensity conditioning (RIC) before unrelated donor (URD) HSCT in children with TDT. Thirty-three children, ages 1 to 17 years, received bone marrow (BM) or umbilical cord blood (UCB) allografts.
View Article and Find Full Text PDF